Navigation Links
Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Date:3/8/2013

ltri termini e frasi simili, nonché da espressioni che, al contrario, li neghino. Le dichiarazioni previsionali si basano su stime e ipotesi formulate dal management e da quest'ultimo ritenute ragionevoli, benché siano intrinsecamente incerte e difficilmente prevedibili. Gli investitori sono invitati a non fare eccessivo affidamento su tali dichiarazioni previsionali.

Le dichiarazioni previsionali implicano rischi e incertezze che potrebbero esplicitarsi in conseguenze reali o esperienze sostanzialmente diverse da quanto in esse espresso o da esse implicitamente desumibile. Tali rischi e incertezze includono, a puro titolo esemplificativo, (1) circostanze economiche che possano influenzare le attività di Takeda , tra cui le condizioni economiche generali in Giappone, Stati Uniti e resto del mondo, (2) pressioni provenienti da competitori e sviluppi da parte della concorrenza, (3) leggi e normative applicabili, (4) successo o fallimento dei programmi di sviluppo del prodotto, (5) azioni condotte delle autorità  regolatorie e tempistica correlata, (6) variazioni dei tassi di cambio, (7) rivendicazioni o preoccupazioni relative alla sicurezza o all'efficacia di prodotti commercializzati, ovvero di prodotti candidati alla fase di sviluppo e, infine, (8) attività d'integrazione con società acquisite.

Le dichiarazioni previsionali contenute in questo comunicato stampa sono valide solo alla data del presente comunicato stampa. Takeda non assume alcun obbligo di rivedere o aggiornare alcuna dichiarazione previsionale in base a nuove informazioni, o a eventi o circostanze future, successive alla data di pubblicazione della presente dichiarazione previsionale. Se Takeda aggiorna o corregge una o più delle presenti dichiarazioni, gli investitori e gli altri soggetti interessati non dovranno da ciò desumerne ulteriori aggiornamenti o correzioni in futuro da parte
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
2. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
7. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
8. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
9. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
10. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
11. Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Talyst Exhibits at the NPPA Summer Conference 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:8/20/2014)... Tuberculosis is one of the most persistent and deadliest ... million people each year. , Scientists who study tuberculosis ... tuberculosis likely spread from humans in Africa to seals ... America and transmitted it to Native people there before ... Mycobacterial Genomes Reveal Seals as a Source of New ...
(Date:8/20/2014)... spawning grounds through fast-moving waters may be at risk, ... , When salmon encounter turbulent, fast-moving water such ... must move upstream using a behaviour known as "burst ... "Days after sockeye passed through extremely fast-moving water, we ... from their spawning grounds," said Nicholas Burnett, a research ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 As ... use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... that two U.S. Senators from New York are urging ... a recall of the devices. In a letter dated ... Democrats, also implored the agency to seriously consider the ...
(Date:8/20/2014)... 2014) Research from Columbia University Medical Center shows ... cancer growth and that blocking nerve signals using surgery ... the disease. The study was conducted by the laboratory ... Chen, MD, PhD, in Norway and is published in ... "Scientists have long observed that human and mouse cancers ...
(Date:8/20/2014)... stimulates stress responses in adults, researchers at Yerkes ... that the amygdala has an inhibitory effect on ... primates. , The results are published this week ... amygdala is a region of the brain known ... and learning about threats. Alterations in the amygdala ...
Breaking Medicine News(10 mins):Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... that Migration/Macrophage Inhibitory factor (MIF) which is an immune cell ... be used in finding drugs which reduces the amount of ... hindered. , Multiple Sclerosis: ,Multiple ... of its own body cells by the immune system leading ...
... A recent study published in the November issue ... that dyspnea, or shortness of breath may be ... ,Although dyspnea is a common symptom, there ... significance among patients referred for cardiac evaluation.,Cardiologists at ...
... plethora of medicinal properties it is a great food. ... such as vampires. Now scientists are finding that garlic, //or ... carcinogens produced by meat cooked at high temperatures. ... releases a chemical called PhIP, a suspected carcinogen. Epidemiological studies ...
... broccoli sprouts may help prevent gastric cancer by reducing Helicobacteri ... and is believed to be a major factor in peptic ... a Japanese team, found that taking a diet with 100 ... H. pylori infection experiencing a significant reduction of H. pylori ...
... Dr. Wan Lian Chua, Psychiatrist, Bradford District Care Trust ... had not given any effective improvement in their condition. ... use of estrogen therapy for treatment of Schizophrenia. Researchers ... used in treating patients before it is tested in ...
... Avian flu pandemic could kill 3 million people in Asia, ... a recession in the world, the Asian Development Bank has ... the likely effects on the region if bird flu produces ... workers being taken ill. 'Growth in Asia would virtually stop,' ...
Cached Medicine News:Health News:Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression 2Health News:A Boon For Gastritis Patients In The Form Of Broccoli 2Health News:ADB Report Warns of Bird-Flu Catastrophe 2
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
Medicine Products: